Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Published byBente Frank Modified over 5 years ago

Similar presentations

Presentation on theme: "Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,"— Presentation transcript:

1 Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow, MBBS, Julia Barkans, Farid Benyahia, BSc, Tsen-Teng Ou, MD, Sun Ying, PhD, A. Barry Kay, MD  Journal of Allergy and Clinical Immunology  Volume 116, Issue 3, Pages (September 2005) DOI: /j.jaci Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 The study design. The times when omalizumab or placebo were administered and the occasions on which skin challenges with allergen and diluent were performed (with or without skin biopsies) are indicated in the flow diagram. The dose of drug administered was mg/kg/IgE (IU/mL) every 4 weeks (solid arrows). Individuals requiring doses between 450 and 750 mg every 4 weeks had the monthly dose administered in 2 equal portions at 2-weekly intervals (solid and interrupted arrows) to minimize the number of injections while maintaining adequate drug levels. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 A, Effect of omalizumab or placebo treatment on the allergen-induced early-phase and late-phase skin responses over the treatment period. Values are expressed as the mean diameter in centimeters (means ± SEMs; n=12 in omalizumab-treated and placebo-treated groups). Significant changes were analyzed by Wilcoxon signed-rank test. B, Percentage changes in the size of allergen-induced early-phase and late-phase skin reactions after treatment with omalizumab or placebo (n=12, both groups). The crossbars represent the median values. Significant changes between groups were analyzed by Wilcoxon rank-sum test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4 Fig 3 Effect of omalizumab or placebo treatment on (A) Congo red+ (CR+) eosinophils and (B) elastase+ neutrophils enumerated in skin biopsies taken 6 hours after diluent or allergen challenge over the treatment period. The results are expressed as the number of positive cells (means ± SEMs) per square millimeter of skin biopsy (n=12, omalizumab; n=12, placebo). The AUC was calculated from 0 to 14 weeks by using the trapezoidal rule for the difference between allergen and diluent (PA–D), and significant differences between groups were analyzed by Wilcoxon rank-sum test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

5 Fig 4 Effect of omalizumab or placebo treatment on (A) CD3+/IL-4+ T cells and (B) CD3+ T cells enumerated in skin biopsies taken 6 hours after diluent (Dil) and allergen (Ag) challenge at baseline and after 14 weeks of treatment. The results are expressed as the number of positive cells (means ± SEMs) per square millimeter of skin biopsy (n=12, omalizumab; n=12, placebo). Statistical differences in the biopsies taken at diluent challenged sites only within each treatment group were analyzed by Wilcoxon signed-rank test, and between-group differences were analyzed by Wilcoxon rank-sum test. Similar analyses for allergen sites alone or allergen minus diluent were both significant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,"

Similar presentations

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma  Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma  Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,
Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects 

Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects 
Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,
Shyam Joshi, MD, David A. Khan, MD 

Shyam Joshi, MD, David A. Khan, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.
The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction  MyLinh Duong, MBBS, Reshma Amin, MD, Adrian J.

The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction  MyLinh Duong, MBBS, Reshma Amin, MD, Adrian J.
Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma  Steven G. Smith, PhD, Akash.

Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma  Steven G. Smith, PhD, Akash.
Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,

Similar presentations

Ads by Google